- A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. Perez, D.J., Harvey, V.J., Robinson, B.A., Atkinson, C.H., Dady, P.J., Kirk, A.R., Evans, B.D., Chapman, P.J. J. Clin. Oncol. (1991)